Lenigron (Timolol, Bimatoprost)

Lenigron is used in ophthalmology to control intra‑ocular pressure in glaucoma‑related conditions.

• Primary open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic‑nerve damage.
• Ocular hypertension: reduces pressure to decrease the risk of progression to glaucoma.
• Secondary open‑angle glaucoma: assists in achieving target pressure when other therapies are insufficient.

• Timolol blocks non‑selective β‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Bimatoprost, a prostaglandin F2α analogue, enhances uveoscleral outflow of aqueous humor. The combined actions result in a greater reduction of intra‑ocular pressure than either agent alone.

Lenigron may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Eye irritation: burning or stinging sensation.
• Blurred vision: temporary visual disturbance.
• Eyelash growth: increased length and thickness.
• Darkening of iris: gradual pigmentation change.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Increased intra‑ocular pressure: paradoxical rise requiring medical attention.
• Persistent eye pain: may indicate corneal involvement.
• Corneal edema: swelling of the cornea affecting vision.
• Uveitis: inflammation of the uveal tract.
• Systemic beta‑blocker effects: bradycardia, hypotension, or bronchospasm.

Before prescribing Lenigron, clinicians should consider patient‑specific factors and monitor for adverse events.

• Cardiovascular assessment: evaluate for bradycardia or heart block.
• Respiratory status: avoid in patients with asthma or severe COPD.
• Intra‑ocular pressure monitoring: check pressure after initiation and periodically.
• Concurrent ocular surgery: discontinue before and after procedures as advised.
• Use with other beta‑blockers: monitor for additive systemic effects.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Lenigron can interact with other medications that affect ocular pressure or systemic beta‑adrenergic activity.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): may cause excessive bradycardia.
• Other ocular beta‑blocker drops: risk of over‑suppression of aqueous production.
• Topical adrenergic agonists (e.g., phenylephrine): may reduce the IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitor eye drops: additive IOP‑lowering effect, monitor pressure.

• Topical corticosteroids: may increase risk of cataract or glaucoma.
• Antihistamine eye drops: possible reduced efficacy of prostaglandin component.